Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slide: 18 of 34

Response Rates in Patients With HCV Genotype 2 or 3 Infection According to Duration of Dual Therapy

Four trials of patients with hepatitis C virus (HCV) genotype 2 or 3 infection found that 24 weeks of dual therapy with ribavirin plus pegylated interferon alfa-2a or with ribavirin plus pegylated interferon alfa-2b was more effective when compared with 12–16 weeks of dual therapy for achieving a sustained virologic response (SVR; pooled relative risk [RR], 1.2; 95-percent confidence interval [95% CI], 1.0 to 1.3). Absolute SVR rates after 24 weeks of dual therapy ranged from 67–78 percent, while SVR rates after 12–16 weeks of dual therapy ranged from 57–62 percent. The strength of evidence for this finding was rated moderate.

Three trials of patients with HCV genotype 2 or 3 infection who achieved a rapid virologic response (defined as undetectable HCV RNA by week 4 of treatment) found no difference between patients randomized to a total of 24 weeks of dual therapy versus 12–16 weeks of dual therapy (pooled RR, 0.99; 95% CI, 0.86 to 1.14). The strength of evidence for this finding was rated moderate.